{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:21:36Z","timestamp":1790011296290,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) is a clinically heterogeneous endocrine disorder with lifelong health risks. Androgen excess, particularly testosterone, plays a key role in the pathophysiology of PCOS. Dihydrotestosterone (DHT) is an active metabolite derived from testosterone, and the total testosterone (TT) to DHT ratio is known as a potential marker of androgen metabolism, which can be used for evaluation of metabolic phenotype. This exploratory study aims to evaluate the association between DHT levels and TT\/DHT ratio with the metabolic parameters and clinical features of PCOS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This cross-sectional study was conducted on 30 patients diagnosed with PCOS based on the Rotterdam 2003 criteria. Clinical, metabolic, and biochemical parameters were assessed. The association between DHT levels, TT\/DHT ratio, and clinical as well as metabolic features was analyzed using ANOVA, Spearman correlation, and independent sample t-tests, with a significance threshold of\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The TT\/DHT ratio was significantly lower in patients with regular menstruation compared to those with oligomenorrhea and amenorrhea (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). A moderate positive correlation was found between DHT levels and BMI (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.487,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), while fasting blood sugar (FBS) was significantly correlated with the TT\/DHT ratio (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.376,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Patients with insulin resistance had a significantly higher TT\/DHT ratio compared to those without insulin resistance (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), whereas DHT levels did not differ significantly between these groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The TT\/DHT ratio could be a useful biomarker to identify PCOS patients with more severe metabolic issues.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-025-02070-4","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:56:14Z","timestamp":1763038574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of dihydrotestosterone levels and total testosterone to dihydrotestosterone ratio with clinical symptoms and metabolic parameters in patients with polycystic ovary syndrome"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1613-9747","authenticated-orcid":false,"given":"Asal","family":"Ebrahimian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-3664","authenticated-orcid":false,"given":"Afshin","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3585-9249","authenticated-orcid":false,"given":"Vahid","family":"Kheyri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1950-0702","authenticated-orcid":false,"given":"Farzad","family":"Najafipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-209X","authenticated-orcid":false,"given":"Vahideh","family":"Sadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"5","key":"2070_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrendo.2018.24","volume":"14","author":"HF Escobar-Morreale","year":"2018","unstructured":"Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270\u201384.","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2070_CR2","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1210\/jc.2011-0039","volume":"96","author":"J Puurunen","year":"2011","unstructured":"Puurunen J, Piltonen T, Morin-Papunen L, Perheentupa A, J\u00e4rvel\u00e4 I, Ruokonen A, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab. 2011;96(6):1827\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2070_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00404-024-07607-x","volume":"310","author":"N Salari","year":"2024","unstructured":"Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1303\u201314.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"2070_CR4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2070_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GRF.0000000000000563","volume":"64","author":"JA Lentscher","year":"2021","unstructured":"Lentscher JA, Decherney AH. Clinical presentation and diagnosis of polycystic ovarian syndrome. Clin Obstet Gynecol. 2021;64(1):3\u201311.","journal-title":"Clin Obstet Gynecol"},{"key":"2070_CR6","doi-asserted-by":"crossref","unstructured":"Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F et al. Polycystic ovary syndrome: Etiology, current Management, and future therapeutics. J Clin Med. 2023;12(4):1454.","DOI":"10.3390\/jcm12041454"},{"key":"2070_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.01.001","volume":"35","author":"MA Sanchez-Garrido","year":"2020","unstructured":"Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020;35:100937.","journal-title":"Mol Metab"},{"issue":"10","key":"2070_CR8","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1210\/jc.2012-1382","volume":"97","author":"H Jones","year":"2012","unstructured":"Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709\u201316.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2070_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.tjog.2019.05.003","volume":"58","author":"Q Liu","year":"2019","unstructured":"Liu Q, Xie YJ, Qu LH, Zhang MX, Mo ZC. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2019;58(4):447\u201353.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"2","key":"2070_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/humrep\/dep384","volume":"25","author":"E Jedel","year":"2010","unstructured":"Jedel E, Waern M, Gustafson D, Land\u00e9n M, Eriksson E, Holm G, et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod. 2010;25(2):450\u20136.","journal-title":"Hum Reprod"},{"issue":"5","key":"2070_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/humupd\/dmu012","volume":"20","author":"JA Barry","year":"2014","unstructured":"Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748\u201358.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"2070_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajum.12096","volume":"21","author":"ME Smet","year":"2018","unstructured":"Smet ME, McLennan A. Rotterdam criteria, the end. Australas J Ultrasound Med. 2018;21(2):59\u201360.","journal-title":"Australas J Ultrasound Med"},{"key":"2070_CR13","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3389\/fendo.2019.00090","volume":"10","author":"SZ Lutz","year":"2019","unstructured":"Lutz SZ, Wagner R, Fritsche L, Peter A, Rettig I, Willmann C, et al. Sex-Specific Associations of Testosterone With Metabolic Traits. Front Endocrinol. 2019;10:2019.","journal-title":"Front Endocrinol"},{"key":"2070_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1053665","volume":"14","author":"C Liu","year":"2023","unstructured":"Liu C, Zhao M, Zhao Y, Hu Y. Association between serum total testosterone levels and metabolic syndrome among adult women in the united States, NHANES 2011\u20132016. Front Endocrinol (Lausanne). 2023;14:1053665.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2070_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1210\/jc.2013-3399","volume":"99","author":"MW O\u2019Reilly","year":"2014","unstructured":"O\u2019Reilly MW, Taylor AE, Crabtree NJ, Hughes BA, Capper F, Crowley RK, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum Androstenedione. J Clin Endocrinol Metab. 2014;99(3):1027\u201336.","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"2070_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.steroids.2008.05.004","volume":"73","author":"C Wang","year":"2008","unstructured":"Wang C, Shiraishi S, Leung A, Baravarian S, Hull L, Goh V, et al. Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: interference and comparison with established methods. Steroids. 2008;73(13):1345\u201352.","journal-title":"Steroids"},{"issue":"4","key":"2070_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5114\/pdia.2014.40925","volume":"31","author":"I Urysiak-Czubatka","year":"2014","unstructured":"Urysiak-Czubatka I, Kmie\u0107 ML, Broniarczyk-Dy\u0142a G. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Postepy Dermatol Alergol. 2014;31(4):207\u201315.","journal-title":"Postepy Dermatol Alergol"},{"key":"2070_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jsbmb.2013.04.001","volume":"138","author":"N Kanaya","year":"2013","unstructured":"Kanaya N, Vonderfecht S, Chen S. Androgen (dihydrotestosterone)\u2013mediated regulation of food intake and obesity in female mice. J Steroid Biochem Mol Biol. 2013;138:100\u20136.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"2070_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1210\/en.2016-1553","volume":"158","author":"S Andrisse","year":"2016","unstructured":"Andrisse S, Childress S, Ma Y, Billings K, Chen Y, Xue P, et al. Low-dose dihydrotestosterone drives metabolic dysfunction via cytosolic and nuclear hepatic androgen receptor mechanisms. Endocrinology. 2016;158(3):531\u201344.","journal-title":"Endocrinology"},{"issue":"2","key":"2070_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1210\/jc.2014-2523","volume":"100","author":"J M\u00fcnzker","year":"2015","unstructured":"M\u00fcnzker J, Hofer D, Trummer C, Ulbing M, Harger A, Pieber T, et al. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(2):653\u201360.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2070_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.5114\/ada.2018.77615","volume":"35","author":"BG Lumezi","year":"2018","unstructured":"Lumezi BG, Berisha VL, Pupovci HL, Go\u00e7i A, Hajrushi AB. Grading of hirsutism based on the Ferriman-Gallwey scoring system in Kosovar women. Adv Dermatol Allergol. 2018;35(6):631\u20135.","journal-title":"Adv Dermatol Allergol"},{"key":"2070_CR22","unstructured":"Riaz Y, Parekh U. Oligomenorrhea(Archived). In: StatPearls. Treasure Island (FL): StatPearls Publishing, copyright \u00a9 2025. StatPearls Publishing LLC.; 2025."},{"key":"2070_CR23","unstructured":"Nawaz G, Rogol AD, Jenkins SM. Amenorrhea. In: StatPearls. Treasure Island (FL): StatPearls publishingcopyright \u00a9 2025. StatPearls Publishing LLC.; 2025."},{"key":"2070_CR24","unstructured":"Atukorala K, Silva N, Amarasiri DL, Fernando S. Changes in serum testosterone during the menstrual cycle -an integrative systematic review of published literature. 2022;3:9\u201320."},{"issue":"4","key":"2070_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11936-011-0130-0","volume":"13","author":"MP McGowan","year":"2011","unstructured":"McGowan MP. Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease. Curr Treat Options Cardiovasc Med. 2011;13(4):289\u2013301.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2070_CR26","doi-asserted-by":"crossref","unstructured":"Patil P, D\u2019Souza N, Ghate S, Nagendra L, Girijashankar H. Free-androgen index in women with polycystic ovarian syndrome: A Meta-Analysis. J Health Allied Sci NU. 2022;13.","DOI":"10.1055\/s-0042-1757445"},{"issue":"4","key":"2070_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.fertnstert.2014.01.003","volume":"101","author":"M Quinn","year":"2014","unstructured":"Quinn M, Shinkai K, Pasch L, Kuzmich L, Cedars M, Huddleston H. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril. 2014;101(4):1129\u201334.","journal-title":"Fertil Steril"},{"issue":"4","key":"2070_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/jwh.2014.5000","volume":"24","author":"AE Joham","year":"2015","unstructured":"Joham AE, Teede HJ, Ranasinha S, Zoungas S, Boyle J. Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. J Womens Health (Larchmt). 2015;24(4):299\u2013307.","journal-title":"J Womens Health (Larchmt)"},{"issue":"6","key":"2070_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4158\/EP.5.6.322","volume":"5","author":"C Ayala","year":"1999","unstructured":"Ayala C, Steinberger E, Smith KD, Rodriguez-Rigau LJ, Petak SM. Serum testosterone levels and reference ranges in reproductive-age women. Endocr Pract. 1999;5(6):322\u20139.","journal-title":"Endocr Pract"},{"issue":"4","key":"2070_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/humupd\/dmp008","volume":"15","author":"L Moran","year":"2009","unstructured":"Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477\u201388.","journal-title":"Hum Reprod Update"},{"key":"2070_CR31","doi-asserted-by":"publisher","DOI":"10.14740\/jem601","author":"S Shah","year":"2019","unstructured":"Shah S, Banu H, Sultana T, Akhtar N, Begum A, Moriom Zamila B, et al. Increased ratio of total testosterone to dihydrotestosterone may predict an adverse metabolic outcome in Polycystic Ovary Syndrome. J Endocrinol Metab. 2019. https:\/\/doi.org\/10.14740\/jem601.","journal-title":"J Endocrinol Metab"},{"issue":"1","key":"2070_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5603\/GP.a2017.0001","volume":"88","author":"U Ambroziak","year":"2017","unstructured":"Ambroziak U, Kury\u0142owicz A, K\u0119pczy\u0144ska-Nyk A, Bartoszewicz Z, Kondracka A, Ja\u017awiec R, et al. Total testosterone to dihydrotestosterone ratio assessed by LC-MS\/MS predicts a worse metabolic profile not only in PCOS patients. Ginekol Pol. 2017;88(1):5\u20138.","journal-title":"Ginekol Pol"},{"key":"2070_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020786","author":"G Fahed","year":"2022","unstructured":"Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23020786.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2070_CR34","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical","year":"2013","unstructured":"World Medical. Association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02070-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-02070-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02070-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:58:32Z","timestamp":1781614712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-025-02070-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-02070-4","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Regional Committee of Research Ethics at Tabriz University of Medical Sciences (Ethics Code: IR.TBZMED.REC.1399.619). Written informed consent was obtained from all participants or their legally authorized representatives prior to enrollment. All procedures were conducted in accordance with the Declaration of Helsinki [\n                      \n                      ].All participants provided informed consent to participate in this study. Participation was voluntary, and all individuals were informed about the purpose of the research, their role, and their right to withdraw at any time without penalty.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}